Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AERO-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AERO-001 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 24, 2025
Lead Product(s) : AERO-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : HCmed Innovations
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration sets forth the framework by which both companies will work together to develop a new nebulized LABA/LAMA combination formulation for the treatment of chronic obstructive pulmonary disease (COPD).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 02, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : HCmed Innovations
Deal Size : Undisclosed
Deal Type : Collaboration